Cite
HARVARD Citation
Tanaka, Y. et al. (2014). AB0415 A New Prognostic Factor to Sustain Remission for 2 Years after Adalimumab Discontinuation & the Clinical Outcomes in RA Patients: Honor Study 2-Years Results. Annals of the rheumatic diseases. p. 944. [Online].